Aclarion loss widens, but balance sheet remains strong
BROOMFIELD — Medical-technology startup Aclarion Inc. (Nasdaq: ACON) lost $1.7 million in the third quarter ended Sept. 30, a 25% increase from a net loss of $1.37 million for the same period a year ago.
But the emerging-growth startup, which has nominal revenue, reported a strong balance sheet, with $11.9 million in assets, including $11.34 million in unrestricted cash on hand. The company has no long-term debt, with just $699,747 in liabilities.
Aclarion leverages Magnetic Resonance Spectroscopy, proprietary signal-processing techniques, biomarkers and augmented intelligence algorithms to optimize clinical treatments.
The company in January completed a $14.4 million public offering of stock and warrants, and completed a 1-for-27 reverse stock split in March. The company’s stock closed Monday at $6.08, up 2 cents.
Medical-technology startup Aclarion Inc. (Nasdaq: ACON) lost $1.7 million in the third quarter ended Sept. 30, a 25% increase from a net loss of $1.37 million for the same period a year ago.
Related Posts
-
Innosphere’s 2026 Life Sciences Incubator will feature a cohort of 38 startups from nine states…
-
Medical-technology startup Aclarion Inc. (Nasdaq: ACON) recently raised $10.4 million in capital through a stock…
-
Aclarion Inc. (Nasdaq: ACON), a Broomfield-based health-care technology that early this year raised $10.4 million…
-
Arpeggio Biosciences Inc., a Boulder-based company that works in the development of pharmaceuticals, has raised…
